



Cancer Targets for Personalized Therapy

Guest Editors:

Dr. Raffaele Di Francia

Scientific directorate ITALIAN
ASSOCIATION OF
PHARMACOGENOMICS AND
MOLECULAR DIAGNOSTICS
(IAPharmagen), via Martiri della
Resistenza 61, 60125 Ancona
Italy.

Dr. Giancarlo Di Blasio

Department of Precision
Medicine, University of Campania
"Luigi Vanvitelli", Via L. De
Crecchio 7, 80138 Napoli, Italy.

Deadline for manuscript
submissions:

closed (31 July 2021)

Message from the Guest Editors

Currently, to plan personalized anticancer therapy, the detection and quantification of novel biomarkers and molecular targets remains a matter of great importance. Recent novel techniques, including in cancer mutational analysis, pharmacogenomics, proteomics, and metabolomics, have given rise to new efforts in performing pathological, biochemical, molecular, and immunological research to study the mechanisms of carcinogenesis, with the final aim of finding the cancer molecular targets which could be applied in clinical practice. This Special Issue aims to present the most recent studies related to the detection of old and novel biomarkers and molecular targets in various cancers. The research could consider different aspects, including A) genetic alterations in cancer, B) diagnosis using novel molecular methods, C) cancer molecular targets, E) in vitro and in vivo pharmacogenomics models for the prevention of toxic and adverse events, F) cancer metabolic and proteomic signatures and altered pathways, G) immunologic biomarkers in cancer immunotherapy, and H) clinical and preclinical studies in drug–nutrient interactions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)